Elutia Inc. reported a net loss of $3.9 million for the third quarter of 2025, a significant decline from a net income of $1.3 million in the same period last year. The company's revenue for the quarter was $3.3 million, down 9.3% from $3.7 million in Q3 2024. This decrease was primarily attributed to a decline in sales from the Women’s Health segment, particularly due to the termination of a distribution agreement with Tiger Aesthetics Medical, which had previously contributed $0.5 million in sales. The Cardiovascular segment, however, saw a 68% increase in sales, reaching $944,000 compared to $562,000 in the prior year.
In terms of operational expenses, Elutia's total operating expenses decreased to $7.1 million from $11 million in the previous year, largely due to a reduction in litigation costs associated with the FiberCel product. The company reported litigation costs of $0.9 million in Q3 2025, a significant drop from $4.7 million in Q3 2024. General and administrative expenses also fell by 18.9% to $3.5 million, reflecting lower non-cash equity compensation. Research and development expenses increased by 55% to $1.1 million as the company intensified its focus on developing its next-generation biologic scaffolds, NXT-41 and NXT-41x.
Elutia's financial position has been impacted by its recent strategic decisions, including the divestiture of its cardiac implantable electronic device (CIED) business to Boston Scientific Corporation for up to $88 million. This transaction, completed on October 1, 2025, is expected to provide the company with additional liquidity, allowing it to focus on its core biologic products. Following the sale, Elutia's cash and cash equivalents stood at approximately $4.7 million as of September 30, 2025, with an anticipated increase to around $44 million post-transaction.
The company has also faced challenges with its accumulated deficit, which reached $247 million as of September 30, 2025. Elutia's management indicated that it expects to continue incurring operating losses and negative cash flows as it advances its product development efforts. The company is actively seeking to raise additional capital through equity offerings or other financing methods to support its operations and growth initiatives. Despite these challenges, Elutia remains focused on leveraging its expertise in biologics and localized drug delivery to improve patient outcomes in reconstructive surgery and related applications.
About ELUTIA INC.
Elutia Inc. develops regenerative medicine products focused on device protection, women's health, and cardiovascular repair. Its offerings include bioenvelopes with antimicrobial properties and acellular dermal matrices to reduce complications like infection, migration, and fibrosis. The company leverages proprietary tissue engineering, strategic partnerships, and a scalable manufacturing model to serve healthcare providers, aiming to improve surgical outcomes and establish standards in implantable device and tissue reconstruction markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.